| Document |
Document Title |
|
JP5701832B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5623013B2 |
Compounds of the formula: Wherein R is selected from the group consisting of H, NH2, and NHBoc; and R′ is selected from the group consisting of H, CH2Ph and tBu, optionally de-protected. Such compounds may be conjugated with a suitable...
|
|
JP5554570B2 |
Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these ...
|
|
JP5436448B2 |
|
|
JP2014503504A |
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...
|
|
JP5291854B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5266499B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5248783B2 |
Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compound...
|
|
JP5230414B2 |
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R...
|
|
JP2013510834A |
The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound ...
|
|
JP5139999B2 |
The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R...
|
|
JP2012149204A |
To provide a method for producing a cyclic amide compound in high efficiency without generating any harmful by-products, and a method for producing a polyamide by ring-opening polymerization of the cyclic amide compound.The method for pr...
|
|
JP4991527B2 |
The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods ...
|
|
JP2012113237A |
To provide an electrophotographic photoreceptor having excellent wear resistance and electric characteristics and significantly improved scratch resistance in an electrophotographic photoreceptor having a surface layer containing a curab...
|
|
JP2012067103A |
To provide a new compound which is useful for treatment of Vancomycin-resistant bacteria infection.Following compounds are illustrated as new peptoid compounds, namely, methyl(2S, 5S, 8R/S)-8-acetamide-2-allyl-9-[6-allyl-9-t-butoxycarbon...
|
|
JP4902361B2 |
Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compound...
|
|
JP4819223B2 |
The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalami...
|
|
JP4787021B2 |
A guanidine compound having a biaryl skeleton represented by the following formula (1), which is useful as a catalyst for various asymmetric reactions. (wherein R1, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon gr...
|
|
JP2011190238A |
To provide a novel cyclic squaric acid amide derivative or a salt thereof, and a prophylactic and/or therapeutic agent comprising at least one thereof as an active ingredient, which is particularly used for diseases against which a calci...
|
|
JP2011140488A |
To provide a peptidomimetic compound which inhibits the NS3 protease of a flavivirus of hepatitis C virus (HCV).The compound is represented by formula (VI).
|
|
JP4709009B2 |
A guanidine compound having a biaryl skeleton represented by the following formula (1), which is useful as a catalyst for various asymmetric reactions. (wherein R1, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon gr...
|
|
JP2011513248A |
The present invention discloses novel Epothilone analogues, their pharmaceutical compositions, their use and their preparations, especially discloses the compounds of general formula I, their preparations and their use for preparing ther...
|
|
JP4628366B2 |
The present invention relates to novel macrocyclic compounds of the formula wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17,...
|
|
JP4630804B2 |
|
|
JP4525982B2 |
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. T...
|
|
JP4521105B2 |
To provide an organic electroluminescence element which has a long life and a high luminous efficacy and emits red light, and to provide a new hydrocarbon compound capable of realizing the organic electroluminescence element. This new hy...
|
|
JP4462999B2 |
|
|
JP4446736B2 |
A compound of the formula (I): wherein A is an aromatic or heteroaromatic ring system or partially or fully reduced derivatives thereof; Q is hydrogen, C 1 -C 12 straight chain, branched or cyclic alkyl substituted with one or more hydro...
|
|
JP4437078B2 |
The invention relates to antibacterial amide macrocycles, to methods for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of illness, especially bacterial infections.
|
|
JP2009544599A |
The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and...
|
|
JP2009544597A |
The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and...
|
|
JP2009275048A |
To provide an NS3 serine protease inhibitor capable of treating, preventing, or ameliorating the symptoms of hepatitis C.Macrocyclic compounds has HCV protease inhibition activity. Each of these compounds typically contains a 15 to 20-me...
|
|
JP4365102B2 |
The present invention relates to a novel sulfonamide derivatives and novel intermediates thereof, preparation thereof, and a pharmaceutical composition comprising the same, and more particularly, to novel sulfonamide derivatives and inte...
|
|
JP4349657B2 |
Aza- and diazacyclohexane and -cyclooctane compounds of the following formula:where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disord...
|
|
JP4320260B2 |
Arylamide derivatives (I) are new. Arylamide derivatives of formula (I) and their salts are new. [Image] X : optionally substituted lower alkylene or alkenylene; G 1O, S or NH; G 2C or N; R aH, halo or optionally substituted alkyl, cyclo...
|
|
JP2009522225A |
The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and...
|
|
JP2009108054A |
To provide a new compound useful for treating infection with vancomycin-resistant bacteria.The new peptoid compound is useful especially against infection with gram-positive bacteria including the vancomycin-resistant and methicillin-res...
|
|
JP4248873B2 |
There is provided a process for the preparation of a compound of formula I, (I), or a pharmaceutically acceptable derivative thereof, wherein A, B, G, R 1 , R 2 , R 3 , R 4 and R 41 to R 46 have meanings given in the description, which p...
|
|
JP4249610B2 |
Compounds of general formula (I): in which: R 1 is hydrogen, C 1 -C 20 alkyl, C 3 -C 10 cycloalkyl, C 4 -C 20 cycloalkylalkyl, aryl, arylalkyl, or two R 1 , taken together, form a straight or cyclic C 2 -C 10 alkylene group or an ortho d...
|
|
JP2009501173A |
The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophy...
|
|
JP2008546763A |
There is provided processes for the preparation of various compounds, including compounds of formulae I, IV and VII, or salts and/or solvates thereof, which compounds are useful intermediates in the synthesis of certain oxabispidines hav...
|
|
JP2008534537A |
The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of medicaments for the treatment and/or proph...
|
|
JP2008526912A |
Macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base form or in a...
|
|
JP4115529B2 |
Farnesyl protein transferase inhibitors e.g. of formula (I) and (II) and their enantiomers, diastereomers, salts, prodrugs and solvates are new: G = a group of formula (i): m, n, r, s, t = 0 or 1; p = 0-2; V, W, X = O, H, R1, R2 or R3; Z...
|
|
JP2008514561A |
The invention relates to antibacterial amide macrocycles and processes for their preparation, their use for the treatment and/or prophylaxis of diseases and their use for the manufacture of medicaments for the treatment and/or prophylaxi...
|
|
JP2007535591A |
Dibenzodiazocine polymers, methods for producing dibenzodiazocine polymers, products formed from dibenzodiazocine polymers, and uses for such dibenzodiazocine polymers are provided.
|
|
JP2007533718A |
Compounds having therapeutic utility are of general formula (1) wherein R, is H, C 1-C6 alkyl optionally substituted with F or C3-C6 cycloalkyl or C2-C4 alkenyl; A is O, CH2 or S(O)n where n is 0-2; one of W, X, Y and Z is N, CH or CR3 a...
|
|
JP2007522135A |
Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions.
|
|
JP2007169215A |
To provide a transition metal salt compound which contains no harmful metal, is simply manufacturable, and can exhibit a thermochromism expressing a specific temperature on the way of ascending or descending temperature by reversible or ...
|
|
JP2007516176A |
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical...
|
